Skip to main content

Ultomiris Side Effects

Generic name: ravulizumab

Medically reviewed by Philip Thornton, DipPharm. Last updated on Oct 16, 2023.

Note: This document contains side effect information about ravulizumab. Some dosage forms listed on this page may not apply to the brand name Ultomiris.

Applies to ravulizumab: solution.

Serious side effects of Ultomiris

Along with its needed effects, ravulizumab (the active ingredient contained in Ultomiris) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking ravulizumab:

More common

Incidence not known

Other side effects of Ultomiris

Some side effects of ravulizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to ravulizumab: intravenous solution.


Frequency not reported: Immunogenicity, increased susceptibility to encapsulated bacterial infections (especially infections caused by Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae, and to a lesser extent, Neisseria gonorrhoeae), life-threatening meningococcal infections (e.g., septicemia and/or meningitis)[Ref]


Rare (0.01% to 0.1%): Infusion reactions (e.g., lower back pain, drop in blood pressure, infusion-related pain)[Ref]


Common (1% to 10%): Pain in extremity, arthralgia[Ref]


Very common (10% or more): Upper respiratory tract infection (e.g., nasopharyngitis, upper respiratory tract infection, oropharyngeal pain, viral

upper respiratory tract infection, rhinitis, respiratory tract infection, rhinorrhea, pharyngitis, upper respiratory tract inflammation) (39%)[Ref]


Common (1% to 10%): Hyperthermia, pyrexia[Ref]


The most frequent adverse drug reactions (greater than 10%) with are upper respiratory tract infection and headache.[Ref]

Nervous system

Very common (10% or more): Headache (32%)

Common (1% to 10%): Dizziness[Ref]


Common (1% to 10%): Diarrhea, nausea, abdominal pain[Ref]

Frequently asked questions


1. Product Information. Ultomiris (ravulizumab). Alexion Pharmaceuticals Inc. 2019.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.